Sellas rises on FDA "fast track" tag for cancer therapy
Brief: Sellas Life Sciences Receives Fast Track Designation From FDA
Brief: Sellas Announces Positive Initial Topline Phase 2a Data Of SLS009 In Acute Myeloid Leukemia
Brief: Sellas Life Sciences Provides Update On Phase 3 Regal Clinical Trial For Galinpepimut-S In Acute Myeloid Leukemia
Brief: Sellas Announces First Patient Dosed In Phase Ib/II Trial Of SLS009 (GFH009) In Relapsed/Refractory Peripheral T-Cell Lymphomas
Brief: Sellas Receives FDA Orphan Drug Designation For SLS009 For Treatment Of Acute Myeloid Leukemia
SELLAS rises on FDA's 'orphan' tag for blood cancer drug
U.S. STOCKS ON THE MOVE-Boston Scientific, Rockwell Medical, Visa
Sellas rises as blood cancer drug succeeds in early-stage study
Brief: Sellas Announces Positive Topline Data In Lymphoma Cohort From Sls009 Phase 1 Dose-Escalation Trial
Brief: Sellas Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S Regal Trial To Continue Without Any Modifications
Sellas Life Sciences Group Inc reports results for the quarter ended in June - Earnings Summary
Brief: SELLAS Life Sciences Group, Inc. Q2 basic EPS USD -0.31
Sellas Life Sciences Group Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Sellas Life Sciences Reports Positive Data In Completed Phase 1 Study Of Galinpepimut-S Combined With Opdivo® In Advanced Malignant Pleural Mesothelioma
Brief: SELLAS Announces First Patient Dosed In Phase 2A Clinical Trial Of GFH009 In Acute Myeloid Leukemia
Brief: Sellas Life Sciences To Present Phase 3 Regal Trial In Progress Poster At 2023 Asco Annual Meeting
Sellas Life Sciences Group Inc reports results for the quarter ended in March - Earnings Summary
Brief: Sellas Life Sciences Group Inc Provides Business Update And Reports First Quarter 2023 Financial Results